Medexus Pharmaceuticals (TSE:MDP) Shares Down 4.4%

Medexus Pharmaceuticals Inc. (TSE:MDP) shares traded down 4.4% during trading on Wednesday . The company traded as low as C$2.15 and last traded at C$2.15. 20,700 shares were traded during trading, a decline of 59% from the average session volume of 50,039 shares. The stock had previously closed at C$2.25.

Wall Street Analysts Forecast Growth

Separately, Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, June 26th.

Medexus Pharmaceuticals Price Performance

The firm has a 50-day moving average price of C$1.86 and a two-hundred day moving average price of C$1.88. The firm has a market capitalization of C$53.08 million, a P/E ratio of 5.43 and a beta of 1.82.

Medexus Pharmaceuticals (TSE:MDP) last announced its quarterly earnings data on Tuesday, June 25th. The company reported C$0.04 earnings per share for the quarter, beating analysts’ consensus estimates of C($0.03) by C$0.07. The company had revenue of C$35.00 million during the quarter, compared to analyst estimates of C$34.96 million. Medexus Pharmaceuticals had a net margin of 5.08% and a return on equity of 26.14%. Sell-side analysts predict that Medexus Pharmaceuticals Inc. will post 0.2462006 earnings per share for the current fiscal year.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.